Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Belmont

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Lupus nephritis: treatment issuesH M Belmont
Current Rheumatology Reports|February 24, 2001
Web alertH M Belmont
Current Rheumatology Reports|December 21, 2000
Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?H M Belmont
Lupus|November 24, 2005
Avascular necrosis prevention with lipitor in lupus erythematosusH M Belmont, E Lydon
Lupus|October 6, 2016
Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problemN Berman, H M Belmont
Lupus|July 30, 2013
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infectionE J Lydon, H M Belmont
Hospital Practice (1995)|May 1, 1998
SLE: mechanisms of vascular injuryS B Abramson, H M Belmont
Arthritis and Rheumatism|April 29, 1998
The role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et alB D Golden, H M Belmont
Clinical and Experimental Rheumatology|August 4, 2009
Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remissionE J Lydon, L Barisoni, H M Belmont
Arthritis and Rheumatism|January 1, 1996
Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endotheliumH M Belmont, S B Abramson, J T Lie
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Lupus nephritis: treatment issuesH M Belmont
Current Rheumatology Reports|February 24, 2001
Web alertH M Belmont
Current Rheumatology Reports|December 21, 2000
Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?H M Belmont
Lupus|November 24, 2005
Avascular necrosis prevention with lipitor in lupus erythematosusH M Belmont, E Lydon
Lupus|October 6, 2016
Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problemN Berman, H M Belmont
Lupus|July 30, 2013
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infectionE J Lydon, H M Belmont
Hospital Practice (1995)|May 1, 1998
SLE: mechanisms of vascular injuryS B Abramson, H M Belmont
Arthritis and Rheumatism|April 29, 1998
The role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et alB D Golden, H M Belmont
Clinical and Experimental Rheumatology|August 4, 2009
Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remissionE J Lydon, L Barisoni, H M Belmont
Arthritis and Rheumatism|January 1, 1996
Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endotheliumH M Belmont, S B Abramson, J T Lie
Pageof 4